Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy

Area of Science:

• Oncology
• Neurology
• Immunotherapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is an established treatment for hematologic malignancies.
• The clinical use of CAR T-cells has expanded, necessitating protocols for managing associated toxicities, particularly neurotoxicity.
• Factors influencing CAR T-cell neurotoxicity risk are not fully understood, and severity can depend on the specific CAR T-cell product.

Purpose of the Study:

• To highlight the importance of clinical vigilance and pre-treatment neurological evaluation for CAR T-cell therapy patients.
• To outline the multidisciplinary approach required for managing CAR T-cell-induced neurotoxicity.
• To discuss diagnostic work-up, treatment strategies, and emerging research on novel CAR T-cell constructs.

Main Methods:

• Comprehensive neurological evaluation, including cognitive assessment and brain MRI, serves as a gold standard baseline.
• Diagnostic work-up involves detailed neurological examination, comparison to baseline, brain imaging, electroencephalogram, and lumbar puncture.
• Management strategies include a team approach with specialists, steroids, tocilizumab for cytokine release syndrome (CRS), and supportive care.

Main Results:

• Neurotoxicity is a significant complication of CAR T-cell therapy, with variable risk factors and severity.
• Early recognition through vigilant monitoring and baseline neurological assessment is critical.
• While predominantly an early and reversible event, late-onset neurotoxicity is increasingly recognized.

Conclusions:

• A multidisciplinary team approach is essential for managing CAR T-cell neurotoxicity.
• Proactive neurological evaluation and vigilant monitoring are key to optimizing patient outcomes.
• Ongoing research aims to develop safer CAR T-cell therapies with reduced toxicity profiles.